SEC Filings

Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine, AYVAKIT/AYVAKYT^® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

Filing date	Form	Description	View
Apr 30, 2015	3	Initial filing by director officer or owner of more than ten percent.	View HTML 0001104659-15-031950.pdf 0001104659-15-031950.rtf 0001104659-15-031950.xls
Apr 30, 2015	3	Initial filing by director officer or owner of more than ten percent.	View HTML 0001104659-15-031956.pdf 0001104659-15-031956.rtf 0001104659-15-031956.xls
Apr 30, 2015	3	Initial filing by director officer or owner of more than ten percent.	View HTML 0001104659-15-031955.pdf 0001104659-15-031955.rtf 0001104659-15-031955.xls
Apr 30, 2015	3	Initial filing by director officer or owner of more than ten percent.	View HTML 0001104659-15-031957.pdf 0001104659-15-031957.rtf 0001104659-15-031957.xls
Apr 30, 2015	3	Initial filing by director officer or owner of more than ten percent.	View HTML 0001104659-15-031953.pdf 0001104659-15-031953.rtf 0001104659-15-031953.xls
Apr 30, 2015	3	Initial filing by director officer or owner of more than ten percent.	View HTML 0001104659-15-031954.pdf 0001104659-15-031954.rtf 0001104659-15-031954.xls
Apr 30, 2015	3	Initial filing by director officer or owner of more than ten percent.	View HTML 0001104659-15-031951.pdf 0001104659-15-031951.rtf 0001104659-15-031951.xls
Apr 30, 2015	3	Initial filing by director officer or owner of more than ten percent.	View HTML 0001104659-15-031952.pdf 0001104659-15-031952.rtf 0001104659-15-031952.xls
Apr 30, 2015	424B4	Form of prospectus disclosing information facts events covered in both forms 424B1 424B3	View HTML 0001047469-15-004205.pdf 0001047469-15-004205.rtf 0001047469-15-004205.xls
Apr 30, 2015	S-8	Securities offered to employees pursuant to employee benefit plans	View HTML 0001104659-15-032381.pdf 0001104659-15-032381.rtf 0001104659-15-032381.xls

Investors & Media

Transformative science, targeted medicines

SEC Filings

Pagination